merck germany - Search News

Merck, SpringWorks

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks

(This Feb. 10 story has been refiled to say 'LOEs (loss of exclusivity),' not 'LOEs (levels of evidence),' in paragraph 13) By Sabrina Valle and Patricia Weiss NEW YORK/FRANKFURT (Reuters) - Merck KGaA,

The Wall Street Journal on MSN · 22h

Germany’s Merck in Talks to Buy SpringWorks Therapeutics

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

BioSpace · 16h

Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential acquisition, though details of its offer have yet to be revealed.

Bloomberg L.P. · 1d

Merck KGaA in Talks to Buy SpringWorks Therapeutics

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring.

Inc · 1d

Merck In Talks to Buy Cancer Drugmaker Springworks

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Hosted on MSN · 1d

Exclusive-Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources say

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics, according to people familiar with the matter.

17m

Merck Foundation Marks International Day of Girls & Women in Science Through Their MARS Awards

Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks International Day of Girls and Women in Science 2025 ...

1don MSN

SpringWorks Stock Jumps More Than 30% on News of Possible Deal

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

12d

Merck to stop lung condition drug study early due to strong efficacy data

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

ABC News7d

Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results